Nucleixa™: Validated Next-Gen Targeted Molecular Nanocarrier Platform | Available for Exclusive IP Acquisition or Licensing
Nucleixa™ is a commercially ready, computationally validated dual-layer molecular nanocarrier platform. Engineered to solve the core industry challenge of active compound degradation and deep cellular penetration, Nucleixa™ enables precise, targeted delivery for high-performance cosmetics, personal care, and advanced therapeutic formulations.
Why Acquire or License Nucleixa™ Today?
Immediate Competitive Moat: A turnkey, plug-and-play IP asset that gives your brand instant technological market leadership without multi-year R&D cycles.
Pre-Validated & Scalable: Fully modeled and computationally optimized, eliminating early-stage technical risk and significantly accelerating time-to-market.
Superior Bio-Absorption: Advanced architectural design engineered for maximal compound stability, deep bio-availability, and targeted cellular release.
Seamless Industrial Integration: Fully compatible with standard manufacturing pipelines and cold-process formulation workflows across skincare, haircare, and personal care lines.
Commercial Opportunity & Urgency
Nucleixa™ is offered as a proprietary IP portfolio ready for deployment. We are currently evaluating direct corporate inquiries for Exclusive Global IP Acquisition, First-Right Licensing, or Co-Development Strategic Partnerships.
Full technical disclosures, architectural data, and computational benchmarks are available under a standard Non-Disclosure Agreement (NDA).
Due to high market relevance and ongoing corporate inquiries, discussions are prioritized on a first-come basis.
Direct Contact for Instant Deal Room & NDA Access:
Email: rasha.work.00@gmail.com
About Molecule GmbH
Molecule provides infrastructure for recording, tokenizing, and funding scientific research through blockchain technology. The platform operates as a discovery engine for tokenized science, enabling researchers to register intellectual property as liquid, onchain assets. By using modular architecture that includes smart contract wallets and NFT-based lab identities, Molecule allows scientific research to be managed, funded, and traded with transparency. The system replaces traditional, gatekept processes with a decentralized approach to intellectual property, where ownership can be shared and research outputs are accessible to a global network of funders and scientists.
This infrastructure is designed to solve inefficiencies in drug development and translational research by aligning the incentives of researchers and funders. By turning IP into a liquid asset class, Molecule seeks to decentralize the ownership, financing, and governance of biotechnology. The platform is used by stakeholders to discover licensing, co-development, and investment opportunities in novel therapeutic technologies, aiming to accelerate the transition of scientific discoveries from the laboratory to practical applications. Through its protocol-level tools and ecosystem, the company facilitates collaborative research and democratizes access to early-stage science.
Inquire about this partnering listing
Looking for
delivered to your inbox.